Varenicline reduces drinking in people with alcohol use disorder, but little is known about the mechanisms underlying this effect. Varenicline targets ␣4␤2 and ␣7 nicotinic acetylcholine receptors, which are associated with several cognitive functions such as working memory. Varenicline may improve drinking outcomes by enhancing cognitive functioning. The current manuscript reports on cognitive outcomes from a placebocontrolled, double-blind human laboratory experiment examining the effects of varenicline on drinking behavior (Verplaetse et al., 2016a) . Participants were 55 adult heavy drinkers who met criteria for an alcohol use disorder. They were randomized to receive varenicline (1 mg/day, 2 mg/day) or placebo. They completed a baseline assessment of cognitive functioning (i.e., digits backward task, continuous performance task) before starting medication. After a medication titration period, they attended a laboratory session (post medication Day 8) where they completed the cognitive assessment battery and an alcohol-primed ad libitum drinking task. Blood was collected to measure plasma varenicline levels. Varenicline produced dose-dependent improvements in working memory. Although there was no significant effect of oral varenicline dose on response time on the continuous performance task, participants with higher levels of plasma varenicline showed greater improvement of reaction time (RT). Among participants receiving 2 mg/day varenicline, larger improvements in working memory were associated less drinking, although mediation analyses did not find a significant indirect effect. These findings suggest that varenicline can improve working memory above baseline levels in heavy drinkers. Varenicline may reduce rates of alcohol use by improving working memory.
have supported the notion that varenicline can reduces rates of harmful drinking (Fucito et al., 2011; Litten et al., 2013) , although a similar clinical trial in people with AUD found no difference between varenicline and placebo in drinking outcomes (de Bejczy et al., 2015) . Overall, this body of work supports that varenicline reduces rates of alcohol use (see Erwin & Slaton, 2014 for a comprehensive review).
Despite consistent evidence that varenicline can reduces rates of drinking, less is known about the mechanisms by which the drug exerts this effect. One possibility is that varenicline reduces rates of drinking by enhancing cognitive performance. Impairments of cognitive functioning is common among individuals with AUD (Bates, Bowden, & Barry, 2002) , and improvements in cognitive functioning may mediate reductions in drinking among people with AUD in treatment (reviewed in Bates, Buckman, & Nguyen, 2013) . Even among substance users without significant cognitive impairments, cognitive enhancements can still be beneficial as it allows better adherence to goal-directed behavior such as limiting drinking or resisting cravings (Houben, Wiers, & Jansen, 2011; Sofuoglu, DeVito, Waters, & Carroll, 2013) . Although it is established that varenicline improves cognitive functioning in smokers (Hong et al., 2011; Patterson et al., 2009; Rhodes, Hawk, Ashare, Schlienz, & Mahoney, 2012; Smith et al., 2009) , many of these studies are conducted in physically dependent smokers who are attempting to quit or are otherwise nicotine deprived. Temporary cognitive impairment is a common symptom of nicotine withdrawal (Shiffman, Paty, Gnys, Kassel, & Elash, 1995) . It is, therefore, difficult to determine in these studies whether varenicline improves cognitive performance by reducing withdrawal symptoms in deprived nicotine users (Ashare & Schmidt, 2014) or produces a more general improvement above baseline. This is an important distinction for understanding whether cognitive enhancing effects of varenicline mediate the drug's effect on drinking.
The current study sought to characterize the effects of varenicline on cognitive functioning in heavy drinking adults by reanalyzing data from a human laboratory study that examined the effects of varenicline (1 mg/day, 2 mg/day) on alcohol use outcomes. Results examining medication effects on drinking outcomes are reported in the parent publication (Verplaetse et al., 2016a) . Cognitive outcomes are not reported in the parent publication; these results are newly reported in the current study. Cognitive performance was assessed using the digit backward task (working memory) and a continuous performance task (RT, sustained attention, and response inhibition). We hypothesized that varenicline would produce a dosedependent increase in cognitive performance, such that participants receiving active varenicline would show improved cognitive performance compared with those receiving placebo. Further, we predicted that varenicline-induced improvement in cognitive functioning would predict drinking outcomes, such that participants who showed the greatest improvement under varenicline would drink less when given ad libitum access to alcohol. In the parent publication for this study, we found significant variability in plasma varenicline levels, even among participants receiving identical varenicline doses. In the current analysis, we also examined the association among degree of improvement in cognitive performance and plasma varenicline levels.
Method Participants
Volunteers were eligible to participate if they were Ն21 years of age and could read and speak English. Data were collected before the transition to the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM5), so all participants met DSM-IV criteria for past 6-month alcohol abuse or dependence. They also endorsed recent patterns of heavy drinking (binge drinking at least once per week over the past 30 days, defined as Ն4/5 drinks in a single episode women and men, respectively). Exclusion criteria included illicit drug use (except for occasional cannabis use defined as use not associated with cannabis dependence), past 30-day use of psychoactive drugs, having sought treatment to reduce alcohol or tobacco use, current suicidal or homicidal ideation, pregnancy or nursing, or a medical condition contraindicating alcohol use (e.g., liver enzymes Ն 3 ϫ normal) or varenicline administration. Volunteers who met criteria for a serious and persistent mental illness (e.g., psychotic spectrum disorder, bipolar disorder) were not invited to participate, nor were those deemed to be at high risk for suicide. Volunteers at risk to undergo alcohol withdrawal, as indicated by an elevated score on the CIWA-Ar (Sullivan, Sykora, Schneiderman, Naranjo, & Sellers, 1989) , were not invited to participate.
Experimental Design
The parent study was a double-blind, placebo-controlled, parallelgroup human laboratory experiment. Participants were randomized to receive varenicline (1 mg/day, 2 mg/day) or placebo. Assignment was stratified by sex and smoking status. Additional methodological details concerning the study design, procedures, and materials are reported in the primary manuscript associated with this experiment (Verplaetse et al., 2016a) . A group of the participants also completed alcohol-challenge sessions between 2 and 3 weeks postrandomization (Verplaetse et al., 2016b) . The parent project is registered with ClinicalTrials.gov, NCT00580645 (Study 1c).
Materials and Measures
Alcohol use. Participants' drinking habits were assessed using the Timeline Follow-back (TLFB) procedure (Sobell & Sobell, 1992) . This protocol uses a structured calendar anchored with holidays and other notable events to assist participants in recording their drinking behavior. Two measures from the TLFB are reported in the current study, including (a) the average number of drinks consumed per week, and (b) the average number of drinking days per week. Participants also completed the alcohol use disorders identification test (AUDIT) as a measure of alcohol use problem severity (Saunders, Aasland, Babor, de la Fuente, & Grant, 1993) . These measures were used to assess for baseline differences between groups in drinking habits.
Digit span backward. The digit span backward is a subtest of the Wechsler intelligence and memory batteries (Wechsler, 1997) . Participants were read a series of numbers and required to repeat the digit sequence back to the research assistant in reversed order. The first items on the task require the participant to recall two numbers and the length of the span increases until the participant This document is copyrighted by the American Psychological Association or one of its allied publishers.
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misses two trials consecutively. This task requires storage of information for mental manipulation of the digits and is considered a measure of working memory capacity (Baddeley, 1992; Conklin, Curtis, Katsanis, & Iacono, 2000; Conway et al., 2005) . Raw scores are reported, indicating the total number of trials where the participants correctly recalled the string of numbers. Possible scores ranged from 0 to 14. Conners' Continuous Performance Task (CPT). The CPT is a computerized assessment tool that measures several aspects of cognitive performance (Conners & Staff, 2000) . Participants viewed a series of letters on a computer monitor for 14 min. They were instructed to respond as quickly as possible to target stimuli (all letters but "X") and the refrain from responding to the infrequent nontarget stimuli ("X"). Criterion variables included RT to target stimuli (RT), variability of response time to go targets (RTvar) and the percentage of nontarget (X) trials during which participants made a response (commission errors).
Procedures
Eligibility screening. The human investigation committee of Yale University approved this study and written informed consent was obtained. Participants underwent an extensive eligibility screening, including physical examination, electrocardiogram, urine toxicology, pregnancy test, and basic blood chemistries.
Medication. Varenicline and matching placebo were provided by Pfizer (NY), and were overencapsulated with riboflavin added to monitor compliance. Varenicline was titrated to steady-state levels over 7 days. Medication compliance was monitored with pill counts and riboflavin marker on Days 5 and 8 (Del Boca, Kranzler, Brown, & Korner, 1996) . Plasma levels were assessed at the start of the laboratory session on Day 8. Additional details about our medication dosing strategies are reported in the parent publication (Verplaetse et al., 2016a) .
Laboratory session. Eight days after starting medication, each participant completed a 14-hr laboratory session conducted at the Yale Center for Clinical Investigation, New Haven, CT. The laboratory procedures were like those used in our previous alcohol self-administration studies , which conform to NIAAA guidelines for alcohol administration (National Advisory Council on Alcohol Abuse & Alcoholism, 2005) . The timing of the laboratory session was as follows: Participants arrived at the laboratory at 8:00 a.m. and their final dose of medication was provided at 9:00 a.m. Smokers were allowed smoke at 10:00 a.m., 12:00 p.m., and 2:00 p.m. on the research unit in a negative pressure room to ensure that they were not nicotine deprived. They completed the cognitive assessment battery between 11:15 am and noon.
Priming dose. The alcohol priming drinks were administered from 3:00 to 3:05 p.m. and consisted of 1 part 80-proof liquor of the participant's choosing and 3 parts mixer chosen from a selection of equally caloric, noncaffeinated, noncarbonated beverages. Doses were calculated to produce a blood alcohol concentration (BAC) of 0.030 g/dl based on Watson's (1989) formula that considers participants' body weight, height, sex, and age to estimate total body water. BAC data following the priming dose are described in the parent publication (Verplaetse et al., 2016a) .
Alcohol self-administration. Participants started the first and second hour of alcohol self-administration 50 and 120 min after consuming the priming drink, respectively. Each ad libitum drinking period lasted 1 hr and participants were able to drink up to four alcoholic beverages (maximum ϭ 8 drinks total over both 1-hr self-administration sessions). Doses were based on Watson's (1989) formula and were calculated such that each drink would raise BAC by 0.015 g/dl. At the beginning of the first self-administration session, participants were given a drinking tab ($24) and told that they could purchase up to four drinks each session. Participants kept $3 for each drink they did not consume, which incentivized their abstinence during this task and modeled a situation in which reducing drinking was a desirable outcome. They were given free access to their drinks and their drinking tab was totaled after the end of the selfadministration periods.
Plasma varenicline levels. Human plasma containing VAR and the internal standard, Varenicline-15 N 2 D 2 was extracted using a solid-phase extraction method for the determination of VAR in human K 2 -EDTA plasma by Worldwide Clinical Trials, Austin, TX. The range of quantitation was 0.0500 to 10.0 ng/ml based on the analysis of 0.500 ml of plasma. Blood was drawn immediately at the beginning of the laboratory session on Day 8.
Data Analyses
One participant was identified as an outlier because of a lack of effort on the digit backward task (i.e., failed to recall 2 items during the first assessment and successfully recalled a string of 7 items during the second assessment; change score ϭ 3.6 SD above mean). Data from this participant were removed. Some participants elected not to complete the computerized assessment potion of the experiment, which included the continuous performance task. The number of participants who completed the CPT included 14, 18, and 17 in the placebo, 1 mg/day, 2 mg/day varenicline conditions, respectively. Analyses of variance and 2 analyses were used to test for group differences in demographic and baseline substance use variables.
Primary outcome variables of interest were scores on the cognitive assessments, plasma varenicline levels, and ad libitum alcohol consumption during the free access period. Data from the cognitive tests were analyzed using 2 (time: baseline vs. laboratory session) ϫ 3 (dose: placebo, 1 mg/day, 2 mg/day) mixed-design analyses of variance (ANOVAs). If the Time ϫ Dose interaction of these omnibus ANOVAs failed to reach significance, we used two a priori analyses to identify significant effects. First, we conducted a reduced-Model 2 (time) ϫ 2 (dose: placebo vs. 2 mg/day) ANOVA to determine whether the maximum dose of varenicline improved cognitive functioning compared with placebo. Models with significant Time ϫ Medication effects were rerun with gender and smoking status (smoker vs. nonsmoker) included as covariates. Second, we used polynomial contrasts to test for a varenicline dose-dependent linear increase in cognitive performance. These polynomial contrasts were conducted using analyses of covariance (ANCOVAs) that were similar to the omnibus mixed-design ANOVAs except that baseline cognitive functioning was included as a covariate and time was not included as a factor. All analyses were first conducted with smoking status and gender included as covariates. If the inclusion of these covariates did not change the significance of either main effect (time or medication condition) or the Time ϫ Medication condition interaction, then results are presented without covariates. This document is copyrighted by the American Psychological Association or one of its allied publishers.
We also examined whether varenicline plasma levels were associated with improvements in cognitive performance. We calculated difference scores (i.e., postmedication performance-premedication performance) that were always coded such that more positive values indicated greater improvements under medication. Zero-order correlation analyses were used to test whether plasma varenicline levels were associated with pre-to postmedication improvements. For these correlations, all participants with available data were included in each analysis, regardless of their medication condition.
The second set of analyses examined whether vareniclineinduced improvements in cognitive performance were associated with ad libitum drinking outcomes. These analyses were guided by the results of the dose-response analyses in that we only conducted these analyses for cognitive functions that evidenced a response to varenicline according to the analyses by oral dose or plasma varenicline levels. Bivariate correlation analyses tested for a significant association among improvements in cognitive performance and the drinking behavior. We tested these correlations with each self-administration period (range ϭ 0 -4) and total number of drinks across both periods (range ϭ 0 -8) as dependent variables. Acknowledging the potential for a nonnormal distribution of ad libitum drinks consumed, we reran these correlations using Spearman's rank order correlations, which are robust against normality violations (Kowalski, 1975) . The correlation coefficients from these analyses were consistent with those from the bivariate analyses, so we present the bivariate correlations below. For significant correlations between cognitive enhancement and drinking outcomes, we conducted mediational analyses to test the significance of the indirect path from medication condition to alcohol selfadministration via improvements in cognitive performance using the product-of-coefficients approach (MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002 ). These analyses only tested for mediation in medication conditions where cognitive enhancement was evident. A bootstrapping procedure (5,000 replications) was used to estimate the SE of the indirect effect.
Results

Demographic, Alcohol Use, and Smoking
Participants demographic information is reported in Table 1 
Association Between Plasma Varenicline and Cognitive Enhancement
Mean plasma varenicline concentration was 2.36 ng/ml (SD ϭ 1.23) among those receiving 1 mg/day and 4.60 ng/ml (SD ϭ 1.86) among those receiving 2 mg/day. Higher concentrations of plasma varenicline were associated with greater improvements in digit span backward, r(53) ϭ 0.299, p ϭ .027, and faster RT on the continuous performance task, r(47) ϭ 0.417, p ϭ .003. There was no significant correlation between plasma varenicline and improvements in RT variability, r(47) ϭ 0.095, p ϭ Ϫ0.516, or commission errors, r(47) ϭ Ϫ0.052, p ϭ .723.
Drinking Outcomes
Correlational analyses summarizing the association between degree of cognitive enhancement and drinking outcomes are presented in Table 2 . As seen in this table, among participants receiving 2 mg/day varenicline, those who showed the most improvement in digit span backward also drank less when given ad libitum access to alcohol. The association is displayed graphically in Figure 3 . This relation was strongest when limiting the analysis to drinks consumed during the first period of free access, but the association was still significant when considering total drinks across both periods. Improvements in response time were associated with less drinking during the second period of free access, although there was no significant relation with total number of drinks across both periods. Medication dose effects on drinking behavior are described in the parent publication (Verplaetse et al., 2016) . Briefly, evidence supported that 2 mg varenicline reduced consumption, primarily in the first period.
Mediation analyses tested the significance of the indirect effect of medication condition (placebo vs. 2 mg/day varenicline) on total number of drinks via improvements in working memory. The indirect effect was not significant, b ϭ Ϫ0.45, SE ϭ 0.55, 95% confidence interval (CI) [Ϫ2.05-0.27], p Ͼ .05. Full mediational analyses are presented in a supplemental table.
Discussion
The current study tested whether varenicline would enhance cognitive functioning in a group of heavy drinking adults. Results were generally consistent with our hypotheses. There was a dosedependent increase in working memory performance observed following the medication titration period, and higher concentrations of plasma varenicline were associated with greater improvements in working memory. This finding is consistent with prior research showing that varenicline can improve working memory in smokers (e.g., Loughead et al., 2010) . Evidence that varenicline speeded RT was mixed. Although there was no significant effect of oral dose on RT, participants who showed higher plasma varenicline levels showed faster RT. These findings provide additional support for our previous conclusions that plasma varenicline is a more sensitive indicator of drug effect compared with oral dose (Verplaetse et al., 2016a) .
Another goal of this study was to test whether vareniclineinduced cognitive enhancement was associated with drinking outcomes in a laboratory model of alcohol-primed drinking. We found that improved working memory and, to a lesser extent, faster RT were associated with less drinking following alcohol prime. This study is the first to show that cognitive enhancement under varenicline is associated with drinking behavior. Working memory is This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
a potential treatment target for the management of substance use disorders (Bickel, Yi, Landes, Hill, & Baxter, 2011; Houben et al., 2011; Sofuoglu et al., 2013) . Our findings here provide direct support for this hypothesis by demonstrating a strong association between medication-induced improvements in working memory and reduced alcohol use following alcohol prime. An interesting find was that there was no significant association among medication response and drinking behavior among participants receiving 1 mg/day varenicline. Other results reported in the parent publication (Verplaetse et al., 2016a) were consistent with this finding. Although there was no significant association between varenicline plasma levels and alcohol drinking overall, a significant relationship emerged when the analysis was restricted to participants with varenicline plasma levels greater than 3 ng/ml, suggesting that a therapeutic threshold must be reached before varenicline influences behavior. An associated study by our group was conducted in a subset of participants in the current sample to determine whether varenicline would reduce alcohol-impairment of cognitive functioning (Verplaetse et al., 2016b) . The study found that participants maintained on varenicline who received a high dose of alcohol (0.08 g/dl) showed less alcohol impairment of working memory (N-back task), processing speed (digit-symbol substitution task), and motor control (pursuit-rotor task) compared with those maintained on placebo. Results of the current study extend these findings by showing that in addition to blocking alcohol impairment of these cognitive functions, varenicline also can enhance cognitive performance above baseline levels. This distinction is important and suggest that varenicline can cause general cognitive enhancement even in people who are abstinent from alcohol, which may help them maintain their abstinence.
Varenicline-induced improvement of working memory is consistent with the known pharmacological profile of the drug. Varenicline is a partial agonist at ␣4␤2 and a full agonist at ␣7 nAChR (Mihalak et al., 2006) . Both receptor subtypes have been implicated in working memory functioning (Chan et al., 2007; Levin, 2002) , because activation of these receptors causes increased dopamine release in brain regions that are activated during working memory tasks (Livingstone et al., 2009 ). Loughead and colleagues (2010) used functional magnetic resonance imaging (fMRI) to examine varenicline-induced changes in brain regions associated with cognitive functioning in nicotine deprived smokers, finding that varenicline increased brain activity during a working memory task in associated regions. Other studies have shown that the ␣7 agonist ABT-126 has a similar enhancing effect on cognitive performance in patients with schizophrenia (Haig, Bain, Robieson, Baker, & Othman, 2016) .
There is a strong theoretical rationale for why pharmacological enhancement of working memory should improve alcohol use outcomes. Dual-process models of substance use propose that drinkers rely on intact higher-order "executive" processes, such as working memory, to adhere to internally represented goals that require resisting more immediate and salient reinforcers (Goldstein & Volkow, 2002) . Although participants in the current study were not treatment seeking, we utilized a laboratory model of motivated abstinence by monetarily incentivizing choosing not to drink. We have successfully used this strategy in the past to model motivated abstinence in medication screening studies with nontreatment seeking substance users (McKee, 2009) . It was especially important to use this approach in the current study because the competing contingencies allowed us to observe how enhanced working memory might influence drinking behavior. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
Despite the robust effect of varenicline on working memory functioning, our study found no evidence that inhibitory control or sustained attention improved under the drug. Other studies have administered batteries of cognitive assessments to people maintained on varenicline to identify which cognitive processes change following varenicline administration. Rhodes and colleagues (2012) found that nonabstinent smokers maintained on varenicline showed a reduction in attentional lapses but no change in inhibitory control on a stopsignal task. Our group (Ashare & McKee, 2012) previously found that varenicline speeded RT but did not have an effect on working memory in nicotine-deprived smokers. Smith and colleagues (2009) found that varenicline improved specific memory functions but had no effect on attention, whereas another study found that varenicline improved a wide array of cognitive functions, including RT and interference control, in smokers with schizophrenia (Shim et al., 2012) . Another study in nonsmokers found that varenicline boosted memory functioning (Mocking et al., 2013) . The discrepancies in findings likely occurred because of the methodological variability among the studies, including differences in their samples (e.g., smokers vs. nonsmokers), testing conditions (e.g., nicotine deprived vs. nondeprived), and the tasks used to assess cognitive functioning. Clearly more research is needed to draw firm conclusions about which cognitive functions are sensitive to varenicline and under what conditions these effects emerge.
Medications that are currently FDA approved to treat alcohol use disorder include naltrexone, disulfiram, and acamprosate. None of these medications are thought to reduce drinking by enhancing cognitive functioning. Indeed, neither naltrexone (Hatsukami, Mitchell, Morley, Morgan, & Levine, 1986) nor disulfiram (Peeke et al., 1979) have an effect on cognitive performance, and acamprosate may even hinder aspects of memory functioning (Schneider et al., 1999 ). This cognitive enhancement strategy for treating substance use disorder is important given that recent theoretical models of substance use disorder emphasize impaired cognitive control as a predisposing and maintaining factor (Goldstein & Volkow, 2011; Lyvers, 2000) . Findings from the current study on varenicline may be particularly important because they identify a new mechanism by which a drug can reduce drinking behavior.
These findings have important implications for pharmacological management of heavy drinking, but findings should be interpreted considering some limitations. First, participants were nontreatment seeking heavy drinkers, and were therefore not highly motivated to reduce their alcohol consumption. It is possible that any improvements in cognitive functioning may have been more beneficial in a group of treatment-seeking participants. Such a possibility could be tested by examining working memory in the context of a clinical trial of varenicline in a group of treatment-seeking heavy drinkers. Second, the current reanalysis only included a single alcohol-use outcome. We did not test the association between medication effects on working memory and alcohol use outside of the laboratory. However, laboratory studies provide important information regarding the mechanisms by which medications can reduce substance use (McKee, 2009 ) and complement findings from larger clinical trials showing that varenicline can reduce alcohol use among treatment-seeking heavy drinkers outside of the laboratory (Litten et al., 2013) . Third, we were not able to show statistically that improvements in working memory explained medication effects on alcohol self-administration using mediation analysis. This null finding may have resulted from Type II error because we had insufficient statistical power to detect mediation effects.
In summary, the current study found that varenicline improved working memory in a group of nontreatment seeking heavy drinkers, an effect that was associated with reduced alcohol use in a laboratory drinking paradigm. These findings are important because they identify a potential mechanism by which varenicline reduces drinking. Although 1 mg/day varenicline produced incremental improvements in working memory, evidence from the current study alongside related investigations (Verplaetse et al., 2016a) suggest that the currently recommended clinical dose (i.e., 2 mg/day) is necessary to produce optimal reductions in alcohol use. Researchers should continue to investigate the potential clinical utility of varenicline for managing alcohol use disorder.
